BCSG1 survivin在浸润性乳腺癌中的表达及预后相关性的研究

目的：探讨BCSG1、surivin蛋白在浸润性乳腺癌中表达的意义及其相关性。方法：采用免疫组化SP法检测100例浸润性乳腺癌组织中BCSG1、surivin蛋白的表达情况，同时取10例正常乳腺组织作对照。结果：BCSG1、survivin在浸润性乳腺癌中阳性表达分别为65％（65／100）、67％（67／100），二者在浸润性乳腺癌中的表达存在着明显的相关性（r=0．288。P〈0．01），进一步发现共表达率达到50％，明显高于c-erhB-2的阳性率，BCSG1、survivin共表达和共表达阴性且c-erbB-2阴性的两组病例淋巴结转移情况分别为86．4％（19／22）和17．6％（3／17），有显著性差异（P〈0．01）。结论：在c-erbB-2阴性表达乳腺癌病例中，BCSG1、survivin共阳性表达者淋巴结转移率明显高于BCSG1和survivin均呈阴性表达者，BCSG1、survivin的共表达可能是不好的预后因素。因此，同时检测BCSG1、survivin和c-erbB-2的表达对乳腺癌生物学行为的判定可能更有价值。     

Survivin和Runx3蛋白在胃癌组织中的表达及其临床意义

目的:探讨Survivin和Runx3蛋白在胃癌组织中的表达情况及临床意义。方法:应用免疫组织化学SP法检测52例手术切除胃癌组织中Survivin和Runx3蛋白的表达水平,分析二者的表达与临床病理特征之间的关系。结果:胃癌组织中Runx3阳性表达率53.8%,与胃癌的肿瘤浸润深度、淋巴转移、远隔转移、临床分期呈负相关(P<0.05)。胃癌组织中Survivin阳性表达率78.8%,与胃癌的肿瘤浸润深度、淋巴转移、临床分期呈正相关(P<0.05)。结论:在胃癌组织中Survivin高表达、Runx3低表达与胃癌的发生发展密切相关,联合检测Survivin和Runx3蛋白对于胃癌的治疗具有指导意义,也可作为判断胃癌预后的参考指标。     

JAK抑制剂AG490诱导乳腺癌细胞凋亡及对Survivin表达的影响

背景与目的:已有研究证实Survivin在多种乳腺癌中可呈高表达且与肿瘤的恶性程度和患者预后密切相关,但是Survivin在乳腺癌细胞中高表达的相关机制尚有待深入了解。本实验拟研究JAK-STAT信号通路抑制剂AG490在人乳腺癌细胞MDA-MB-231中对Survivin表达以及对肿瘤细胞增殖、凋亡的影响。方法:以MDA-MB-231细胞为研究对象,应用AG490后,用Westernblot检测细胞中P-STAT3、Survivin的蛋白表达变化、RT-PCR检测SurvivinmRNA的变化;用MTT法检测细胞增殖活性的改变;用流式细胞术检测细胞凋亡的情况。结果:AG490使MDA-MB-231细胞中P-STAT3和Survivin的蛋白表达减少,同时细胞的增殖活性降低,凋亡增多。P-STAT3/β-actin用药前为0.74,AG49040μmol/L作用24h后为0.21;Survivin/β-actin用药前为1.09,40μmol/LAG490作用24h后为0.28。40μmol/LAG490作用24h后细胞出现“亚G1”峰,凋亡率为5.62%;AG49040μmol/L,作用48h后细胞凋亡率为28.81%。结论:AG490可诱导MDA-MB-231细胞凋亡、减少Survivin的表达。     

Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer

Alternative splicing of survivin mRNA gives rise to multiple isoforms, that is, survivin and 3 splice variants, survivin-2B, survivin-3B and survivin-DeltaEx3. The aim of this study was to compare the expression of survivin, survivin-2B and survivin-DeltaEx3 in normal breast tissue, fibroadenomas, primary breast cancer and axillary nodal metastases. Survivin, survivin-2B and survivin-DeltaEx3 mRNA were measured using semiquantitative RT-PCR. In the primary carcinomas, we related mRNA for each form of survivin to both survivin protein and apoptosis. For each type of breast tissue, survivin was the predominant form detected, being present in 146 out of 156 (93.6%) primary breast carcinomas, 11 out of 11 (100%) axillary nodal metastases, 21 out of 31 (67.7%) fibroadenomas and five out of 22 (22.7%) specimens of normal breast tissue. Levels of the three forms of survivin were significantly higher in the carcinomas compared to normal breast tissue (P < 0.0001). Levels of both survivin-2B and survivin-DeltaEx3 but not survivin were significantly higher in nodal metastases than primary carcinomas. Survivin mRNA levels correlated significantly with survivin protein. Finally, both survivin and survivin-DeltaEx3 but not survivin-2B correlated positively with apoptosis. Although survivin, survivin-2B and survivin-DeltaEx3 were all detected in both malignant and nonmalignant breast tissue, the predominant form was survivin. Our results suggest that the different forms of survivin may have different roles in apoptosis in breast cancer.     

Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status.

PURPOSE: Angiogenesis is essential for tumor growth. Vascular endothelial growth factor (VEGF) is one of the most potent angiogenic cytokines. In breast cancer, tumor VEGF has been shown to have a good correlation with relapse-free survival. The aim of this study was to determine the relation of serum VEGF levels to the various indices of breast cancer and known tumor markers carcinoembryonic antigen and CA15.3. EXPERIMENTAL DESIGN: Preoperative serum VEGF levels were determined in 200 women with breast cancer and compared with serum VEGF levels in 88 healthy female controls. RESULTS: The serum VEGF levels of the cancer patients as a group were significantly elevated compared with those of the controls (P < 0.0005). VEGF levels were elevated in patients with invasive cancer of ductal/no specific type, ductal carcinoma in situ, and estrogen receptor (ER)-positive tumors. Patients with lobular carcinoma and ER-negative tumors had serum VEGF levels comparable with those in the controls. VEGF was more sensitive than CA15.3 and carcinoembryonic antigen in detecting breast cancer. CONCLUSIONS: Preoperative serum VEGF detects breast cancer with a sensitivity of 62.1%. The relationship to cancer type and ER status may have future therapeutic implications. Additional long-term studies are required to determine the prognostic significance of serum VEGF.     

P33~(ING1)和Survivin及Ki67蛋白在食管癌发生发展中的作用

目的 检测P33ING1、Survivin和Ki67蛋白在食管正常黏膜、单纯增生、不典型增生、浸润癌中的表达情况,分析这三种蛋白在食管癌不同病变区域中的表达及与食管癌病理特征的关系.方法 采用免疫组化方法 检测P33ING1、Survivin和Ki67蛋白在51例食管癌大体标本中的不同病变区域的表达.结果 P33ING1蛋白从正常黏膜、单纯增生、不典型增生增生、浸润癌呈渐进性低表达,而Survivin和Ki67蛋白则呈渐进性高表达.三种蛋白在正常黏膜中的表达与不典型增生及浸润癌中的表达差异有显著性(P<0.01);P33ING1蛋白在食管癌中的表达与癌肿浸润深度(肌层至全层)呈负相关(P<0.05),与分化程度(G1、G3)呈正相关(P<0.05 );Survivin蛋白表达与食管癌分化程度、淋巴结转移有关(P<0.05);P33ING1蛋白在浸润癌中的低表达与Survivin和Ki67蛋白高表达呈负相关(P<0.01).结论 Survivin功能的激活、Ki67增殖及P33ING1功能的下调可能共同对抗细胞凋亡,参与食管癌的发生发展.三者有可能为临床上食管癌早期诊断、相关治疗及预后研究提供新的手段.     

Survivin和Cox-2在乳腺浸润性导管癌组织中的表达及临床意义

目的：研究乳腺浸润性导管癌组织中Survivin和Cox-2蛋白的表达情况及与临床病理指标的关系,并探讨两种蛋白间的关系.方法：应用免疫组化SP法检测79例乳腺癌组织、30例癌旁组织中Survivin和Cox-2的表达,并分析各蛋白的表达与临床病理学指标间的关系.结果：79例乳腺癌组织中Survivin和Cox-2的表达率分别为64.56％ （51/79）和58.22％ （46/79）,与癌旁组织相比差异有统计学意义（P＜0.05）.Survivin和Cox-2的表达与乳腺癌的组织学分级、临床分期和淋巴结转移有关（P＜0.05）,而与患者年龄大小、肿瘤大小无关（P＞0.05）.在乳腺癌中Survivin和Cox-2表达水平呈正相关（P＜0.05）.结论：Survivin和Cox-2高表达与乳腺癌的发生、发展及浸润转移有关,可作为判断乳腺癌生物学行为和预后的重要指标.